

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

SU-DIPG-VI

RRID:CVCL_IT40

Type: Cell Line

Proper Citation

RRID:CVCL_IT40

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_IT40

Proper Citation: RRID:CVCL_IT40

Description: Cell line SU-DIPG-VI is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse intrinsic pontine glioma

Defining Citation: [PMID:24777482](#), [PMID:25366336](#), [PMID:25939062](#), [PMID:28823557](#), [PMID:33319914](#), [PMID:34215733](#), [PMID:34732238](#)

Comments: Donor information: Established from a sample taken just after the death at age 7 of McKenna Wetzel. When McKenna died, the Wetzels donated to researchers at Stanford University the tissues that allowed this cell line to be derived. They also created the McKenna Claire Foundation's whose mission is to help cure pediatric brain cancer by raising awareness, increasing community involvement and funding research.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DIPG-VI

Synonyms: SU-DIPGVI, SUDIPGVI, SU-DIPG-6, DIPG 6, DIPG-6, DIPG6, SJHGG042550, Stanford University-Diffuse Intrinsic Pontine Glioma-VI

Cross References: BTO:BTO_0005954, cancercellines:CVCL_IT40, Wikidata:Q54970735

ID: CVCL_IT40

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260905T182515+0000

Ratings and Alerts

No rating or validation information has been found for SU-DIPG-VI.

No alerts have been found for SU-DIPG-VI.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Calvo Fernández E, et al. (2026) Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states. *Nature genetics*, 58(5), 1112.

Eytan K, et al. (2025) Raphin-1 mediates the survival and sensitivity to radiation of pediatric-type diffuse high-grade glioma via phosphorylated eukaryotic initiation factor 2?-dependent and -independent processes. *Molecular oncology*, 19(9), 2648.

McNicholas M, et al. (2023) A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities. *Cancer discovery*, 13(7), 1592.

Siddaway R, et al. (2022) Splicing is an alternate oncogenic pathway activation mechanism in glioma. *Nature communications*, 13(1), 588.

Furth N, et al. (2022) H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape. *Cell reports*, 39(7), 110836.

Harpaz N, et al. (2022) Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. *Molecular cell*, 82(14), 2696.

Fortin J, et al. (2020) Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. *Cancer cell*, 37(3), 308.